IPO Timeline
Broker Results (T-2)
2020-12-17
Some brokers release in afternoon
Grey Market (T-1)
2020-12-18
Afternoon
HKEX Allotment (T-1)
2020-12-18
Evening
Registrar Allotment (T-1)
2020-12-18
Evening
Listing Day (T)
2020-12-21
First day of trading
Company Overview
| Stock Name | 加科思藥業集團有限公司 - B |
|---|---|
| Stock Code | 01167 |
| Company Full Name | 加科思藥業集團有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注於腫瘤療法。 |
| Listing Date | 2020-12-21 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區科創六街88號F2樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.jacobiopharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 14.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 34.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 675,360,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 14.42 |
|---|---|
| First Day Open | HK$ 15.98 |
| First Day Change | 3.00% |
| First Day Volume | 63740700.0 |
| First Day Turnover | 1022840000.0 |
Use of Proceeds
| Use of Proceeds | 1、約88.0%，或143.4百萬美元（1,111.5百萬港元），將主要用于產品的臨床開發及商業化； 2、約8.0%，或13.0百萬美元（101.0百萬港元）將用于建造符合GMP標準的內部生產設施； 3、約4.0%，或6.5百萬美元（50.5百萬港元）將用于我們的一般企業及營運資金用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | HBC Asia Healthcare Opportunities V LLC | 77,515,200 HKD | — | 5.74% | — | 6 months | 2021-06-21 |
| 2 | LAV Prime Limited | 116,272,800 HKD | — | 8.61% | — | 6 months | 2021-06-21 |
| 3 | Matthews Asia Funds | 116,272,800 HKD | — | 8.61% | — | 6 months | 2021-06-21 |
| 4 | Octagon Investments Master Fund LP | 77,515,200 HKD | — | 5.74% | — | 6 months | 2021-06-21 |
| 5 | Sage Partners Master Fund | 38,757,600 HKD | — | 2.87% | — | 6 months | 2021-06-21 |
| 6 | Superstring Capital Master Fund LP | 38,757,600 HKD | — | 2.87% | — | 6 months | 2021-06-21 |
Directors & Management
| Chairman | 王印祥 |
|---|---|
| Company Secretary | 薛青;鐘明輝 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 王印祥及關連人士(28.58%);Center Laboratories, Inc.(12.77%);高瓴資本管理有限公司(7.37%);Qiming Corporate GP VI, Ltd.(6.43%);LAV Biosciences Fund IV, L.P.(5.46%) |
|---|
IPO Timeline
